Rank
358
Gilead Sciences
Courtesy of Gilead Sciences
- Previous Rank316
- Revenues ($M)30390
- Revenue Percent Change-6.9
- Profits ($M)13501
- Profits Percent Change-25.4
- Assets ($M)56977
- Employees9000
Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs' prices (among other problems) has contributed to the biotech giant's 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it's sitting on a massive bed of cash.
Company Information
| CEO | John F. Milligan |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| HQ Location | Foster City, CA |
| Website | www.gilead.com |
| Years on Global 500 List | 3 |
| Employees | 9,000 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $30,390 |
| Profits ($M) | $13,501 |
| Assets ($M) | $56,977 |
| Total Stockholder Equity ($M) | $18,887 |
Profit Ratios
| Profit as % of Revenues | 44.4% |
| Profits as % of Assets | 23.7% |
| Profits as % of Stockholder Equity | 71.5% |